Health Care & Life Sciences » Biotechnology | Redx Pharma PLC

Redx Pharma PLC | Income Statement

Fiscal year is October-September. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
30,474.00
129
Cost of Goods Sold (COGS) incl. D&A
239.00
252.00
139.00
262.00
-
-
Gross Income
239.00
252.00
139.00
262.00
-
-
SG&A Expense
9,490.00
9,919.00
11,940.00
16,510.00
18,055.00
10,898
EBIT
9,729.00
10,171.00
12,079.00
14,554.00
12,092.00
11,685
Unusual Expense
-
-
-
556.00
11,078.00
215
Non Operating Income/Expense
6,401.00
6,157.00
3,543.00
162.00
962.00
1,731
Interest Expense
253.00
249.00
348.00
526.00
368.00
1
Pretax Income
3,581.00
4,263.00
8,825.00
15,407.00
1,646.00
10,146
Income Tax
389.00
910.00
650.00
114.00
118.00
1,301
Consolidated Net Income
3,192.00
3,353.00
8,175.00
15,521.00
1,528.00
8,845
Net Income
3,192.00
3,353.00
8,175.00
15,521.00
1,528.00
8,845
Net Income After Extraordinaries
3,192.00
3,353.00
8,175.00
15,521.00
1,528.00
8,845
Net Income Available to Common
3,192.00
3,353.00
8,175.00
15,521.00
1,528.00
8,845
EPS (Basic)
0.05
0.05
0.14
0.20
0.01
0.07
Basic Shares Outstanding
65,466.60
65,466.60
58,455.40
78,945.90
113,022.80
126,447.90
EPS (Diluted)
0.05
0.05
0.14
0.20
0.01
0.07
Diluted Shares Outstanding
65,466.60
65,466.60
58,455.40
78,945.90
113,046.40
126,447.90
EBITDA
9,490.00
9,919.00
11,940.00
14,292.00
12,419.00
11,521
Other Operating Expense
-
-
-
2,218.00
-
752
Non-Operating Interest Income
-
-
59.00
67.00
38.00
24

About Redx Pharma

View Profile
Address
Alderley Park
Macclesfield CQ SK10 4TG
United Kingdom
Employees -
Website http://redxpharma.com
Updated 07/08/2019
Redx Pharma Plc engages in the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer and fibrosis. The company was founded by Neil David Murray, Peter Jackson, Derek Lindsay, and Norman Molyneux on September 7, 2010 and is headquartered in Macclesfield, the United Kingdom. .

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.